Novartis AG (NOVN) Stock Forecast & Price Target

Compare

27 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOVN Analyst Ratings

Hold

5 Buy

6 Hold

2 Sell

Based on 13 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOVN Stock 12 Month Forecast

Average Price Target

CHF102.42

▲(3.61% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is CHF102.42 with a high forecast of CHF120.00 and a low forecast of CHF89.00. The average price target represents a 3.61% change from the last price of CHF98.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","121":"CHF121","93.25":"CHF93.3","102.5":"CHF102.5","111.75":"CHF111.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF102.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF89.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,93.25,102.5,111.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.54,102.96000000000001,104.38000000000001,105.80000000000001,107.22,108.64,110.06,111.48,112.9,114.32000000000001,115.74000000000001,117.16,118.58,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.54,101.60769230769232,101.67538461538462,101.74307692307693,101.81076923076924,101.87846153846154,101.94615384615385,102.01384615384616,102.08153846153847,102.14923076923077,102.21692307692308,102.28461538461539,102.35230769230769,{"y":102.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.54,100.57538461538462,99.61076923076924,98.64615384615385,97.68153846153847,96.71692307692308,95.7523076923077,94.78769230769231,93.82307692307693,92.85846153846154,91.89384615384616,90.92923076923077,89.96461538461539,{"y":89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF120.00

Average Price TargetCHF102.42

Lowest Price TargetCHF89.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Weston

UBS

CHF95

Hold

-3.89%

Downside

Reiterated

09/12/25

UBS Sticks to Their Hold Rating for Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF95→CHF94

Sell

-4.91%

Downside

Downgraded

09/12/25

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

Emmanuel Papadakis

Deutsche Bank

CHF120

Buy

21.40%

Upside

Reiterated

09/10/25

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

Shirley Chen

Barclays

CHF90

Sell

-8.95%

Downside

Reiterated

09/10/25

Barclays Sticks to Their Sell Rating for Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

CHF95

Hold

-3.89%

Downside

Reiterated

09/09/25

J.P. Morgan Reaffirms Their Hold Rating on Novartis AG (NOVN)

Thibault Boutherin

Morgan Stanley

CHF100→CHF105

Hold

6.22%

Upside

Reiterated

09/08/25

Morgan Stanley Sticks to Its Hold Rating for Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

CHF111

Hold

12.29%

Upside

Reiterated

09/04/25

Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk ConcernsWe flag 5 high risk-reward pipeline reads 2H25-FY26E, with first being full data for ianalumab in Sjogren’s (possibly at ACR-25 in Oct), where focus is whether efficacy is clinically meaningful vs bar framed by KOLs (below). Key reads in FY26E: pelacarsen Lp(a) in CVD, zigakibart (anti-APRIL) in IgAN, ianalumab 1L ITP, remi (BTKi) in RMS and abelacimab (anti-FXI) in SPAF. We see each as positive risk-reward but riskier with low-sd $bn peak sales and individually not enough to change mid-term narrative given NOVN’s lower growth outlook/patent exposure (Cosentyx 29E, Kisqali 31E, Kesimpta 31-33E). Despite likely EPS momentum and a decent catalyst path, we stay Neutral on valuation; our target 14.5x 26E PE is higher than would be implied by forecasted growth rate, which accounts for breadth of pipeline. We tweak our EPS on updated product forecasts.

Benjamin Jackson CFA

Jefferies

CHF100

Hold

1.16%

Upside

Reiterated

09/02/25

Jefferies Remains a Hold on Novartis AG (NOVN)

Veda Pharmyne

TR | OpenAI - 4o

CHF108→CHF116

Buy

17.35%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

David Evans

Kepler Capital

CHF106

Buy

7.23%

Upside

Reiterated

08/19/25

Kepler Capital Reaffirms Their Buy Rating on Novartis AG (NOVN)

Florent Cespedes

Bernstein

CHF115→CHF108

Buy

9.26%

Upside

Reiterated

08/04/25

Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)

Kerry Holford

Berenberg Bank

CHF89

Hold

-9.96%

Downside

Reiterated

07/22/25

Novartis AG (NOVN) Receives a Hold from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/18/25

Novartis AG (NOVN) Gets a Buy from DZ BANK AG

Peter Verdult

Exane BNP Paribas

CHF95

Buy

-3.89%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at OutperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Novartis (NOVN:SW) (NYSE: NVS) with a Outperform rating and a price target of CHF95.00.

Eric Le Berrigaud

Stifel Nicolaus

CHF109

Hold

10.27%

Upside

Reiterated

01/31/25

Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Weston

UBS

CHF95

Hold

-3.89%

Downside

Reiterated

09/12/25

UBS Sticks to Their Hold Rating for Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF95→CHF94

Sell

-4.91%

Downside

Downgraded

09/12/25

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

Emmanuel Papadakis

Deutsche Bank

CHF120

Buy

21.40%

Upside

Reiterated

09/10/25

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

Shirley Chen

Barclays

CHF90

Sell

-8.95%

Downside

Reiterated

09/10/25

Barclays Sticks to Their Sell Rating for Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

CHF95

Hold

-3.89%

Downside

Reiterated

09/09/25

J.P. Morgan Reaffirms Their Hold Rating on Novartis AG (NOVN)

Thibault Boutherin

Morgan Stanley

CHF100→CHF105

Hold

6.22%

Upside

Reiterated

09/08/25

Morgan Stanley Sticks to Its Hold Rating for Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

CHF111

Hold

12.29%

Upside

Reiterated

09/04/25

Benjamin Jackson CFA

Jefferies

CHF100

Hold

1.16%

Upside

Reiterated

09/02/25

Jefferies Remains a Hold on Novartis AG (NOVN)

Veda Pharmyne

TR | OpenAI - 4o

CHF108→CHF116

Buy

17.35%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

David Evans

Kepler Capital

CHF106

Buy

7.23%

Upside

Reiterated

08/19/25

Kepler Capital Reaffirms Their Buy Rating on Novartis AG (NOVN)

Florent Cespedes

Bernstein

CHF115→CHF108

Buy

9.26%

Upside

Reiterated

08/04/25

Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)

Kerry Holford

Berenberg Bank

CHF89

Hold

-9.96%

Downside

Reiterated

07/22/25

Novartis AG (NOVN) Receives a Hold from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/18/25

Novartis AG (NOVN) Gets a Buy from DZ BANK AG

Peter Verdult

Exane BNP Paribas

CHF95

Buy

-3.89%

Downside

Initiated

04/16/25

Eric Le Berrigaud

Stifel Nicolaus

CHF109

Hold

10.27%

Upside

Reiterated

01/31/25

Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

+1.83%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +1.83% per trade.

3 Months

xxx

Success Rate

19/26 ratings generated profit

Average Return

+3.15%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.08% of your transactions generating a profit, with an average return of +3.15% per trade.

1 Year

David EvansKepler Capital

Success Rate

26/26 ratings generated profit

Average Return

+11.47%

reiterated a buy rating 29 days ago

Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.47% per trade.

2 Years

xxx

Success Rate

26/26 ratings generated profit

Average Return

+16.57%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +16.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVN Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOVN has received 19 Buy Ratings, 23 Hold Ratings, and 4 Sell Ratings. NOVN average Analyst price target in the past 3 months is 102.42.

Each month's total comprises the sum of three months' worth of ratings.

NOVN Financial Forecast

NOVN Earnings Forecast

Next quarter’s earnings estimate for NOVN is CHF1.79 with a range of CHF1.70 to CHF1.87. The previous quarter’s EPS was CHF1.93. NOVN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.

NOVN Sales Forecast

Next quarter’s sales forecast for NOVN is CHF10.96B with a range of CHF10.66B to CHF11.42B. The previous quarter’s sales results were CHF11.61B. NOVN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 55.07% of the time in the same period. In the last calendar year NOVN has Outperformed its overall industry.

NOVN Stock Forecast FAQ

What is CH:NOVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis AG’s 12-month average price target is 102.42.

What is CH:NOVN’s upside potential, based on the analysts’ average price target?

Novartis AG has 3.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis AG a Buy, Sell or Hold?

Novartis AG has a consensus rating of Hold, which is based on 5 buy ratings, 6 hold ratings and 2 sell ratings.

What is Novartis AG’s share price target?

The average share price target for Novartis AG is 102.42. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF120.00 ,and the lowest forecast is CHF89.00. The average share price target represents 3.61% Increase from the current price of CHF98.85.

What do analysts say about Novartis AG?

Novartis AG’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Novartis AG?

To buy shares of CH:NOVN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novartis AG (NOVN) Stock Forecast & Price Target

NOVN Analyst Ratings

NOVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis AG

NOVN Analyst Recommendation Trends

NOVN Financial Forecast

NOVN Earnings Forecast

NOVN Sales Forecast

NOVN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts